



A service of the [U.S. National Library of Medicine](#)
and the [National Institutes of Health](#)

Select **19457609**

1: [Cancer Lett.](#) 2009 May 18. [Epub ahead of print]



Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.

[Yuki K](#), [Natsume A](#), [Yokoyama H](#), [Kondo Y](#), [Ohno M](#), [Kato T](#), [Chansakul P](#), [Ito M](#), [Kim SU](#), [Wakabayashi T](#).

Center for Genetic and Regenerative Medicine, Nagoya University Hospital, Nagoya, Japan.

The response of cancer patients to interferon (IFN) treatment is long-lasting, indicating that IFN may act on small cancer stem cell populations. Glioma-initiating cells (GICs) can self-renew and induce the formation of heterogeneously differentiated tumor cells and are resistant to chemotherapeutic agents like temozolomide. In this study, we showed that via STAT3 signaling, IFN-beta suppressed the proliferation, self-renewal, and tumorigenesis of GICs, induced their terminal differentiation to mature oligodendroglia-like cells, and exhibited synergistic cytotoxicity with temozolomide. Therefore, IFN may be a potential therapeutic agent for inducing the terminal differentiation of GICs.

PMID: 19457609 [PubMed - as supplied by publisher]
